b'SIU EVENTSPreliminary Educational ObjectivesThe overarching goal of the programme is to understand and increase participants abilities to review and evaluate recent research findings in the field of GU oncology and apply these to clinical care, with the goal of improving clinical outcomes and patient quality of life.THE B2B PROGRAMME WILL ADDRESSAT THE END OF THIS PROGRAMME, THREE KEY COMPONENTS: PARTICIPANTS WILL BE ABLE TO:Competence: ability to apply knowledgeEvaluate the benefits and risks of various treatment plus strategy in practice when necessary. options across the treatment continuum in UC, RCC, and PCa.Practice performance: the application of new Analyze novel agents and treatment approaches for the evolving management of GU cancers based on strategies or skills in the practice setting. emerging clinical data. Discuss strategies to identify and manage adverse Gap: the difference between what physiciansevents related to systemic treatment, including are currently doing in practice and what isimmunotherapy.considered best or ideal practice.Evaluate the role of imaging or genetic markers in guiding treatment decision-making. Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.PRELIMINARY AGENDA November 11, 2022BLADDER CANCER Limits of partial nephrectomy in localized RCCFocus on T1 Bladder Cancer Debate: Is there a best regimen for first-line therapy in mRCC?Optimal surgical management of T1 Bladder CancerMolecular risk stratification and precision therapy for PROSTATE CANCERT1 Bladder Cancer Germline testing: who and how?Can ctDNA and utDNA be used to monitor NMIBC?MRI for optimal assessment of T1 Bladder Cancer Update on AI-derived predictive biomarkersDebate: Adjuvant chemotherapy vs. adjuvant IO after Ultrahypofractionation for treatment of localizedradical cystectomy Prostate Cancer Case-Based Panel Discussion: Anything but radical cystectomy!Management of pN1 diseaseBladder preservation in 2022 PSMA theranostics to target Prostate CancerAdvances in intraluminal therapy of upper tract urothelialMetastatic Prostate Cancer: standards of care, challenges, carcinoma progress & personalized therapy General GU Talk: Financial toxicity and treatment access FIVE PRACTICE-CHANGING ADVANCESKIDNEY CANCER ON THE HORIZONDebate: Adjuvant therapy should be offered to all high-riskBladder Cancerpatients post nephrectomy Kidney CancerBest options for the treatment of metastatic non-clear cell RCCProstate CancerPre-operative identification and optimal treatment of sarcomatoid RCC*At time of print. Subject to change.12 SIUuMAG|MARCH 2022, VOLUME 3, NO. 1'